Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021...
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Despite the development of cancer biomarkers and targeted therapies, most cancer patients do not have a specific biomarker directly associated with effective treatment options. We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). O...
Alternative Titles
Full title
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0f96566457eb478681a046ba79ade1bd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0f96566457eb478681a046ba79ade1bd
Other Identifiers
ISSN
2397-768X
E-ISSN
2397-768X
DOI
10.1038/s41698-024-00774-9
